AlzeCure Pharma (Q1 Review): Advancing toward Phase IIa with NeuroRestore ACD856 - Redeye

Redeye returns with an update following AlzeCure’s Q1 earnings release. The company prepares its projects for clinical development, with a key focus on initiating a Phase IIa study with NeuroRestore ACD856 in Alzheimer’s patients in 2026, supported by the EIC grant. We reiterate our fair value range of SEK0.4-10, with a base case of SEK5.

Länk till analysen i sin helhet: https://www.redeye.se/research/1165142/alzecure-pharma-q1-review-advancing-toward-phase-iia-with-neurorestore-acd856?utm_source=finwire&utm_medium=RSS